Dr. Mark Pegram is the Suzy Yuan-Huey Hung Professor of Medicine at the Stanford Cancer Institute. During his career path to tenured full professor at UCLA, Dr. Pegram, in collaboration with Dr. Dennis Slamon at UCLA, and scientists at Genentech, Inc., played a significant role in the pre-clinical and early clinical development of trastuzumab (Herceptin®) for the treatment of HER2-positive breast cancer. In 2012, he was recruited to the SCI from the Sylvester Comprehensive Cancer Center, where he served as the Associate Director for Clinical Research, and acting Division Chief of Hematology/Oncology for a faculty of over 70 researchers. In 2013, he assumed the role of Associate Director for Clinical Research within the SCI. He is a breast cancer physician and researcher who has chaired the DOD breast cancer research program panel and is the recipient of the NCI Director’s Service Award, the Sylvester Outstanding Cancer Research Award, the Hope Award from the HERS Breast Cancer Foundation, and is a Fellow of the Breast Cancer Research Foundation. His research focuses on new therapeutic strategies targeting HER2-positive breast cancers. Dr. Pegram was the lead author on the papers describing pre-clinical synergy between multiple chemotherapeutics and trastuzumab, and the first phase II clinical trial of trastuzumab plus chemotherapy. In addition, he was the senior author of the pivotal trial of letrozole plus lapatinib – leading to an FDA approval, and co-author on the pivotal trials of trastuzumab plus chemotherapy, and T-DM1, both published in the New England Journal of Medicine, and leading to FDA approvals.